Neuropharmacology

Lipoprotein Related Disease Models: NPC1 knock outs and ApoB-100 Mice - November, 2013

Genetic defects in the lipid/cholesterol metabolism may result in such severe diseases as Niemann-Pick C1 (NPC1 mutation) or familial hypercholesterolemia (among others ApoB-100 mutations). Two characterized models offered by QPS will provide novel insights in understanding cholesterol metabolism or in evaluating the efficacy of developmental compounds against Niemann-Pick disease, familial hypercholesterolemia or life style diseases such as atherosclerosis or coronary heart disease.

If you are interested in ourunique tools to screen developmental compounds interfering with lipid metabolism, oxidative stress and/or cognition, please click on the link below:

For more information on QPS’ Neuropharmacology contract research services and capabilities, please contact:

Robert Wronski, PhD, MBA 
Internal BD Manager 
QPS Austria
Parkring 12, A-8074 Grambach
Austria

Phone: + 43 316 25 8111 212
Mobile: + 43 664 266 61 64
Email: robert.wronski@qps.com

back
top
20 years in pharma R&D navigation